Orum Therapeutics is a private, clinical stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD² approach to provide dual-precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Company’s proprietary platforms generated using the TPD² approach include the GSPT1 platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the GSPT1 platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Boston, US and Daejeon, South Korea.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2016
Investors 1
| Date | Name | Website |
| 20.06.2023 | Premier Pa... | premierpar... |
Mentions in press and media 3
| Date | Title | Description |
| 17.07.2019 | Orum Therapeutics Raises $30M in Series B Financing | Orum Therapeutics, a Cambridge MA- and Daejeon, South Korea-based private biotech company, raised a $30m Series B financing. New investors IMM Investment, Smilegate Investment, KTB Network, and Stassets Investment joined existing investors ... |
| 15.06.2017 | Term Sheet — Thursday, June 15 | GREEDY BASTARDS Good morning. Paid Content What you need to know about growing cyberattacks From ExtraHop • That price would be more than double Slack’s latest private valuation from 2016. • Amazon is not known for its monster acquisitions.... |
| 14.06.2017 | Orum Therapeutics Raises $8M in Series A Financing | Orum Therapeutics, a Daejeon, South Korea-based private biotech company creating novel therapeutics, completed an $8m Series A financing. Backers included InterVest, KB Investment (KBIC)/Solidus Investment, and LB Investment. In conjunction... |